NYSE:CVS

CVS Health Corp (CVS)

98.04
+0.98 (1.01%)
as of Jun 10, 2026, 7:59:58 pm Market Open.
411 watching
0
Investor Insights
star iconJun 10, 2026, 12:00 am

This summary was created by AI, based on 9 opinions in the last 12 months.

CVS Health Corp has seen a significant rise in its stock price, recently jumping 8% to reach a three-year high after beating earnings and raising its full-year forecast. Experts note that while the stock may appear cheap, caution is warranted as some underlying issues persist, particularly with visibility and execution. CVS is more than just a drug store chain; it is also a managed care company that is undergoing a transformation driven by strong leadership. Although the retail pharmacy space faces weaknesses, their health insurance segment is showing substantial improvement with notable revenue growth, leading to positive adjustments in guidance. Overall, CVS is viewed as a turnaround story that presents growth opportunities as competitors falter, and its valuation relative to earnings suggests that it may still have room to increase further.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
PAST TOP PICK
(A Top Pick May 03/19, Up 12%) It held in there nicely. It set back to its book value after a good run. He would still buy it.
DON'T BUY

Healthcare is one of the best three sectors over the last 50 years. Eli Lily is a better choice. He's not in drugstores, because they are cyclical, such as 2008-9 when they got hit in a slow economy. Drugstores make their money buying impulse items in addition to their drugs, and people don't buy in tough times. He suggest Costco which fulfills prescriptions, but sells groceries. And Amazon is getting into this space.

HOLD
This has been hurt badly due to the virus. They had a good last quarter. She would continue to hold it. The risk of regulatory concern is lower too now that Biden looks like the likely Democrat candidate.
PARTIAL BUY

There are two positives there for them. They are a drug distributor and they are now into healthcare insurance. With Sanders looking less likely to be the Democrat candidate, they should see some benefit. He is concerned there is a lot of competition out there for this space, like Costco, Walmart and others. Near term he could see a bottom coming in the share price and will be looking to pick away at it.

WAIT
He had owned this a couple of years ago. He has favoured other health plays, but is watching this again. With Bernie Sanders rising in the Democratic leadership race, the threat to the pharma community is rising again. There is headline risk in this space. A share price drop of $5 might bring him in on this stock, but waiting is probably best.
TOP PICK
An integrated health company, including insurance. This business model lets them add value to customers. There's some uncertainty about US healthcare reform which has hit CVS's valuation of 9x earnings with a 9% free cash flow yield. Amazing value. (Analysts’ price target is $84.08)
TOP PICK
Becoming a full health-care services company. It's all about scale. Paid down debt. Trades at 10x, cheap right now. Dividend may not grow for next couple of years. Yield is 2.78%. (Analysts’ price target is $84.04)
BUY

The pharma retailers are becoming full-service, like Loblaw buying Shoppers Drug Mart. There's better growth in drugstore bricks and mortar retailing. Trades at a reasonable multiple. You're fine to hold this.

COMMENT
He likes this space. It's toppy now, with $80 as the top, a level it rarely breaks. Just be aware of that.
DON'T BUY
He does not hold this currently. It is in the middle of the pack in terms of valuation metrics, especially since it holds a higher level of debt.
COMMENT
This hasn't been a name for them. They are focusing more on the retail side and he wants a more pure play on healthcare. They have developed their pharmacy benefit managers. At around 10x earnings, it's fairly inexpensive but their debt levels are fairly high. They are trying to vertically integrate.
HOLD
It has had a great move since June. It is going to run into resistance in the high $70 range. He thinks you should focus on companies that get a boost from a stronger economy. We have come off a mid-cycle slow down. Earnings growth at CVS-N is in the single digits but less likely to get a boost from a stronger economy. He thinks it will under-perform the general market over the next year.
BUY
She is worried about their leverage. They are doing a lot of interesting things with US healthcare. They want to do 50% of the things one can do at the family doctor. It seems like a compelling story. She thinks it will be a good multi-year run. (Analysts’ price target is $81.00)
BUY

CVS vs. Walgreens Prefers CVS. Walgreens missed their recent numbers. Walgreens is purely a pharmacy company, which faces competitive threats from Amazon and Walmart. In contrast, CVS is vertically integrated; they bought insurer Aetna for example. Pays a 3% yield. However, CVS did borrow heavily to buy Aetna, but generally CVS is in much better financial shape than Walgreens.

BUY
He is very positive on this one. They were stuck in the mud for a while, but their business plan is now coming into fruition. This is a company that is redefining health care in the US. No longer just a pharmacy, they are into health insurance and into benefits management. They have set up health hubs to serve people who do not have access to emergency medical needs. (Analysts’ price target is $81.54)
Showing 196 to 210 of 464 entries